WEBULL
News
ARWR
63.59
-0.42%
-0.27
Weekly Report: what happened at ARWR last week (0216-0220)?
Weekly Report · 14h ago
Analysts Conflicted on These Healthcare Names: Idexx Laboratories (IDXX), Arrowhead Pharmaceuticals (ARWR) and Disc Medicine (IRON)
TipRanks · 6d ago
Weekly Report: what happened at ARWR last week (0209-0213)?
Weekly Report · 02/16 10:16
Arrowhead Pharmaceuticals (ARWR) Valuation Check After Earnings Jump And S&P Index Move
Simply Wall St · 02/15 04:36
Is Arrowhead’s Profit Surge and S&P MidCap 400 Move Altering The Investment Case For Arrowhead Pharmaceuticals (ARWR)?
Simply Wall St · 02/14 03:37
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens
Benzinga · 02/13 18:45
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality
Simply Wall St · 02/12 10:50
Arrowhead Joins S&P 400 As Profitability Shifts Investor Focus
Simply Wall St · 02/11 06:24
Breaking Down Arrowhead Pharma: 18 Analysts Share Their Views
Benzinga · 02/10 12:00
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Protara Therapeutics (TARA) and Kodiak Sciences (KOD)
TipRanks · 02/10 11:30
Weekly Report: what happened at ARWR last week (0202-0206)?
Weekly Report · 02/09 10:17
Arrowhead Pharmaceuticals Earnings Call Flags Pivotal 2026
TipRanks · 02/08 00:16
Arrowhead Pharmaceuticals (ARWR) Q1 Profit Challenges Bearish Narratives On Earnings Quality
Simply Wall St · 02/07 10:09
Arrowhead price target lowered to $78 from $81 at Morgan Stanley
TipRanks · 02/06 15:40
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript
The Motley Fool · 02/06 13:25
Analysts Are Bullish on These Healthcare Stocks: Cigna (CI), Envista Holdings (NVST)
TipRanks · 02/06 13:01
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Illumina (ILMN) and Rigel (RIGL)
TipRanks · 02/06 12:20
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Resmed (RMD) and Bristol-Myers Squibb (BMY)
TipRanks · 02/06 11:50
ARROWHEAD PHARMACEUTICALS <ARWR.O>: MORGAN STANLEY CUTS TARGET PRICE TO $78 FROM $81
Reuters · 02/06 11:32
Arrowhead outlines pivotal 2026 milestones with REDEMPLO launch, $1.33B capital boost, and robust cardiometabolic pipeline
Seeking Alpha · 02/06 05:35
More
Webull provides a variety of real-time ARWR stock news. You can receive the latest news about Arrowhead Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.